Zogenix data blunder trips up FDA filing for epilepsy drug Fintepla by Amirah Al Idrus Tuesday, April 9, 2019 The FDA has refused to review the new drug application for Zogenix's Fintepla because of missing and incomplete data.
Using Pfizer’s smoking-cessation drug Chantix to control neurons by Angus Liu Thursday, March 14, 2019 The ion channel-based chemogenetic platform involves pairing cell surface proteins with Chantix to selectively control neuronal activities.
Medtronic launches deep brain implant for epileptic seizures by Conor Hale Wednesday, February 20, 2019 The medtech giant has begun rolling out its therapy in the U.S., with the treatment of its first commercially implanted patient.
Axovant spins out its epilepsy drug team with $100M lined up by Conor Hale Thursday, February 14, 2019 Axovant spun off its small molecule team into Arvelle Therapeutics, as it continues its march toward a sole focus on gene therapies.
27. Diacomit by Beth Snyder Bulik The anticonvulsant approved to treat seizures in Dravet syndrome patients older than age two will launch in the U.S. January 2019.
16. Epidiolex by Amirah Al Idrus With a nod for two rare forms of epilepsy, GW Pharma’s Epidiolex became the first cannabis-based prescription medicine in the U.S.
New discoveries in hematology and epilepsy—News of Note by Arlene Weintraub Monday, December 3, 2018 The week’s news included antibodies that lower the risks of bone marrow transplants and a new way to target a mutation in epilepsy.
Solving an old neuroscience puzzle may lead to epilepsy therapy by Angus Liu Friday, November 9, 2018 Discovery made by Virginia Tech scientists on perineuronal nets could open up new approach for acquired epilepsy.
Backed by Bain, Pfizer loads prime CNS assets into new biotech by Phil Taylor Tuesday, October 23, 2018 Pfizer has followed through on its pledge to divest a hunk of its neuroscience R&D, spinning several programs into a new company called Cerevel.
Supernus adds epilepsy drug via $185M Biscayne buy by Phil Taylor Friday, September 14, 2018 Supernus makes a return to epilepsy R&D, buying the developer of a traditional Chinese medicine-derived drug for $15 million upfront.
